Allakos (NASDAQ: ALLK)
Allakos Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Allakos Company Info
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
News & Analysis
Why Shares of Allakos Are Up Wednesday
The stock is bouncing back from a recent 52-week low.
Why Allakos Stock Skyrocketed Nearly 9% Higher Today
The company is poised to report a critical set of clinical data in the coming months.
Why Allakos Stock Was Heating Up Today
A notable analyst upgrade had investors piling into this clinical-stage biotech stock today.
Why Allakos Stock Is on Fire Today
Investors appear to be getting into position ahead of a major upcoming catalyst.
Why Allakos Stock Sank 17.3% in February
The biotech stock has lost roughly 96% of its value over the last year.
Why Allakos Stock Plummeted 87.5% in the Last Month of 2021
The biotech stock is now down roughly 93% over the last year.
Why Allakos Stock Is Crashing Today
The company announced disappointing results from two clinical studies.
3 Healthcare IPOs From 2018 That Have Already Doubled
Find out why these new healthcare stocks keep climbing, while most of their peers have underwhelmed.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.